Boomerang Medical Raises $20M Series B for Bioelectronic Inflammatory Bowel Disease Treatment
Summary
Boomerang Medical has raised $20 million in a Series B financing to advance clinical trials of its bioelectronic neuromodulation device for inflammatory bowel disease. The company's approach uses targeted nerve stimulation to modulate the gut-brain axis and reduce inflammatory responses in conditions like Crohn's disease and ulcerative colitis. The funding will support a pivotal clinical trial program.
Why it matters
Boomerang Medical represents the expanding frontier of bioelectronic medicine into inflammatory conditions where traditional pharmaceuticals have significant limitations. The $20M Series B demonstrates continued investor interest in using neurotechnology principles to treat conditions beyond the central nervous system. The gut-brain axis is an area of intense scientific interest, and Boomerang's device-based approach could offer a new treatment paradigm for millions of patients with inflammatory bowel disease.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial